FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161036151> ?p ?o ?g. }

• W2161036151 endingPage "74" @default.
• W2161036151 startingPage "70" @default.
• W2161036151 abstract "Objective To review three prospective, randomized, placebo-controlled, double-blind clinical studies of formoterol (Foradil Aerolizer; Novartis Pharmaceuticals; Basel, Switzerland) at dosages of 12 μg and 24 μg bid for the treatment of patients with asthma. Data sources Clinical studies submitted to the US Food and Drug Administration in support of the approval of Foradil Aerolizer for marketing in the United States. Results More patients treated regularly with formoterol, 24 μg bid, had a serious asthma exacerbation than did patients who had been treated with placebo. In the first study, 4 of 135 adult patients (3%) who had been treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to none of 136 placebo-treated patients. In the second study, 5 of 136 patients (3.7%) treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to 2 of 141 placebo-treated patients (1.4%). In the third study, 11 of 171 pediatric patients (6.4%) treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to none of 176 placebo-treated patients. Conclusion Regular use of high-dose inhaled formoterol (24 μg bid) may be associated with more frequent serious asthma exacerbations. To review three prospective, randomized, placebo-controlled, double-blind clinical studies of formoterol (Foradil Aerolizer; Novartis Pharmaceuticals; Basel, Switzerland) at dosages of 12 μg and 24 μg bid for the treatment of patients with asthma. Clinical studies submitted to the US Food and Drug Administration in support of the approval of Foradil Aerolizer for marketing in the United States. More patients treated regularly with formoterol, 24 μg bid, had a serious asthma exacerbation than did patients who had been treated with placebo. In the first study, 4 of 135 adult patients (3%) who had been treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to none of 136 placebo-treated patients. In the second study, 5 of 136 patients (3.7%) treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to 2 of 141 placebo-treated patients (1.4%). In the third study, 11 of 171 pediatric patients (6.4%) treated with formoterol, 24 μg bid, had a serious asthma exacerbation compared to none of 176 placebo-treated patients. Regular use of high-dose inhaled formoterol (24 μg bid) may be associated with more frequent serious asthma exacerbations." @default.
• W2161036151 created "2016-06-24" @default.
• W2161036151 creator A5014423063 @default.
• W2161036151 creator A5018878300 @default.
• W2161036151 creator A5044953985 @default.
• W2161036151 creator A5061940636 @default.
• W2161036151 creator A5079380290 @default.
• W2161036151 creator A5080207754 @default.
• W2161036151 date "2003-07-01" @default.
• W2161036151 modified "2023-10-17" @default.
• W2161036151 title "Serious Asthma Exacerbations in Asthmatics Treated With High-Dose Formoterol" @default.
• W2161036151 cites W1795103282 @default.
• W2161036151 cites W1966561808 @default.
• W2161036151 cites W1981992864 @default.
• W2161036151 cites W1999011146 @default.
• W2161036151 cites W2006363187 @default.
• W2161036151 cites W2010822535 @default.
• W2161036151 cites W2087666617 @default.
• W2161036151 cites W2088520852 @default.
• W2161036151 cites W2090786287 @default.
• W2161036151 cites W2098894574 @default.
• W2161036151 cites W2107458343 @default.
• W2161036151 cites W2121540830 @default.
• W2161036151 cites W2124984210 @default.
• W2161036151 cites W2152785448 @default.
• W2161036151 cites W2155589243 @default.
• W2161036151 cites W2185554765 @default.
• W2161036151 cites W2331287401 @default.
• W2161036151 doi "https://doi.org/10.1378/chest.124.1.70" @default.
• W2161036151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12853504" @default.
• W2161036151 hasPublicationYear "2003" @default.
• W2161036151 type Work @default.
• W2161036151 sameAs 2161036151 @default.
• W2161036151 citedByCount "160" @default.
• W2161036151 countsByYear W21610361512012 @default.
• W2161036151 countsByYear W21610361512013 @default.
• W2161036151 countsByYear W21610361512014 @default.
• W2161036151 countsByYear W21610361512015 @default.
• W2161036151 countsByYear W21610361512016 @default.
• W2161036151 countsByYear W21610361512017 @default.
• W2161036151 countsByYear W21610361512018 @default.
• W2161036151 countsByYear W21610361512019 @default.
• W2161036151 countsByYear W21610361512020 @default.
• W2161036151 countsByYear W21610361512021 @default.
• W2161036151 countsByYear W21610361512022 @default.
• W2161036151 countsByYear W21610361512023 @default.
• W2161036151 crossrefType "journal-article" @default.
• W2161036151 hasAuthorship W2161036151A5014423063 @default.
• W2161036151 hasAuthorship W2161036151A5018878300 @default.
• W2161036151 hasAuthorship W2161036151A5044953985 @default.
• W2161036151 hasAuthorship W2161036151A5061940636 @default.
• W2161036151 hasAuthorship W2161036151A5079380290 @default.
• W2161036151 hasAuthorship W2161036151A5080207754 @default.
• W2161036151 hasConcept C126322002 @default.
• W2161036151 hasConcept C142724271 @default.
• W2161036151 hasConcept C162156334 @default.
• W2161036151 hasConcept C204787440 @default.
• W2161036151 hasConcept C27081682 @default.
• W2161036151 hasConcept C2776042228 @default.
• W2161036151 hasConcept C2776136866 @default.
• W2161036151 hasConcept C2777014857 @default.
• W2161036151 hasConcept C2779871671 @default.
• W2161036151 hasConcept C42219234 @default.
• W2161036151 hasConcept C535046627 @default.
• W2161036151 hasConcept C71924100 @default.
• W2161036151 hasConceptScore W2161036151C126322002 @default.
• W2161036151 hasConceptScore W2161036151C142724271 @default.
• W2161036151 hasConceptScore W2161036151C162156334 @default.
• W2161036151 hasConceptScore W2161036151C204787440 @default.
• W2161036151 hasConceptScore W2161036151C27081682 @default.
• W2161036151 hasConceptScore W2161036151C2776042228 @default.
• W2161036151 hasConceptScore W2161036151C2776136866 @default.
• W2161036151 hasConceptScore W2161036151C2777014857 @default.
• W2161036151 hasConceptScore W2161036151C2779871671 @default.
• W2161036151 hasConceptScore W2161036151C42219234 @default.
• W2161036151 hasConceptScore W2161036151C535046627 @default.
• W2161036151 hasConceptScore W2161036151C71924100 @default.
• W2161036151 hasIssue "1" @default.
• W2161036151 hasLocation W21610361511 @default.
• W2161036151 hasLocation W21610361512 @default.
• W2161036151 hasOpenAccess W2161036151 @default.
• W2161036151 hasPrimaryLocation W21610361511 @default.
• W2161036151 hasRelatedWork W1673187729 @default.
• W2161036151 hasRelatedWork W1957770986 @default.
• W2161036151 hasRelatedWork W1985426726 @default.
• W2161036151 hasRelatedWork W1998365118 @default.
• W2161036151 hasRelatedWork W2030653132 @default.
• W2161036151 hasRelatedWork W2031143026 @default.
• W2161036151 hasRelatedWork W2038923405 @default.
• W2161036151 hasRelatedWork W2040683479 @default.
• W2161036151 hasRelatedWork W2112264559 @default.
• W2161036151 hasRelatedWork W2165087980 @default.
• W2161036151 hasVolume "124" @default.
• W2161036151 isParatext "false" @default.
• W2161036151 isRetracted "false" @default.
• W2161036151 magId "2161036151" @default.
• W2161036151 workType "article" @default.